Key Drivers
- Liquidity Cushion
- Cash Burn
- Weak Profitability
AIAI Summary
BEAM is increasingly a near-term regulatory/launch catalyst story rather than just a long-duration platform bet, with a strong $1.2B cash runway reducing dilution risk, but investors should now focus on execution and timing—especially risto-cel BLA/launch progress and BEAM-302 pivotal advancement—because any delay or clinical miss could quickly pressure the still-demanding valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity Cushion
- •Cash Burn
- •Weak Profitability
BEAM has a very strong liquidity buffer, but persistent losses, negative free cash flow, and rich valuation keep the investment case under pressure.
Price Behavior
Key Price Behavior Insights:
- •Lower high
- •Failed rebound
- •Support test
BEAM weakened about 11% over the last month after failing at $31.85-$32.33 resistance and breaking below the late-April rebound zone, leaving the short-term trend bearish and near support at $27.11-$27.93.
Sharp rebound from $27.11 to $32.32, then quick breakdown after
Sentiment & News
Key News Insights:
- •Clinical progress
- •Regulatory milestones
- •Strong cash runway
Beam Therapeutics reported encouraging clinical progress across BEAM-302 and BEACON, with key regulatory milestones ahead and a strong cash runway supporting execution into 2029.
The news is modestly positive, as execution on lead programs and a long runway improve visibility despite the larger-than-expected quarterly loss
Similar Companies in Healthcare
Other companies in the same sector with AI ratings